Lobbying Information
Subject Matters
- Economic Development
- Health
- Industry
- Intellectual Property
- International Trade
- Research and Development
- Science and Technology
- Taxation and Finance
Subject Matter Details
Legislative Proposal, Bill or Resolution
- Food and Drug Act - An Act respecting food, drugs, cosmetics and therapeutic devices. Discussions relating to progressive licensing and the modernization of the Food and Drug Act.
- Patent Act - An Act respecting patents of invention with regard to Intellectual Property Protection for pharmaceutical products - federal court decisions that have changed the disclosure requirements regarding the utility of an invention.
Policies or Program
- Free trade treaty agreement as it relates to the North American Free Trade Agreement (NAFTA) and free trade negotiations as it relates to Columbia, India, and the European Union
- Pharmaceutical pricing policy arising from the jurisdiction of the Patented Medicines Prices Review Board (PMPRB)
- The government's Science and Technology Strategy potential policies and programs pertaining to the biopharmaceutical industry
Regulation
- Intellectual Property - Changes to Patented Medicine (Notice of Compliance) (PMNOC) regulations - important regulations that can affect Eli Lilly Canada's business
- Patented Medicine Notice of Compliance (PMNOC) Regulations - enforcement of Intellectual Property with respect to the Canadian pharmaceutical industry.
Communication Techniques
-
Written communication
-
Oral communication
Government Institutions
-
Agriculture and Agri-Food Canada (AAFC)
-
Federal Economic Development Agency for Southern Ontario (FedDev)
-
Finance Canada (FIN)
-
Global Affairs Canada (GAC)
-
Health Canada (HC)
-
House of Commons
-
Indigenous and Northern Affairs Canada
-
Innovation, Science and Economic Development Canada (ISED)
-
Patented Medicine Prices Review Board (PMPRB)
-
Prime Minister's Office (PMO)
-
Privy Council Office (PCO)
-
Senate of Canada
Government institutions added through a monthly communication report
- Treasury Board Of Canada Secretariat (TBS)
In-house Corporation Details
Description of activities
Pharmaceutical manufacturer, research and development, commercial operations.
Responsible officer name and position during the period of this registration
Lisa Matar,
President and General Manager
Government funding
No government funding was received during the last completed financial year.
In-house Corporation Contact Information
Address:
3650 Danforth Avenue
Toronto, ON M1N 2E8
Canada
Telephone number:
416-699-7222
Fax number:
416-694-0487
Parent Company Information
Eli Lilly Canada Inc. is not a subsidiary of any other parent companies.
Subsidiary Beneficiary Information
- BIOTECANADA
-
(Partner)
420 - 130 ALBERT STREET
OTTAWA, ON K1P 5G4
Canada
- Elanco Animal Health
-
150 Research Park Lane, Suite 120
Guelph, ON N1G 4T2
Canada
- Innovative Medicines Canada / Medicaments Novateurs Canada
-
(Partner)
55 Metcalfe Street, Suite 1220
Ottawa, ON K1P 6L5
Canada
Lobbyists Details
Senior Officers whose lobbying activities represent less than 20% of their Duties
Senior Officers and Employees whose lobbying activities represent 20% or more of their Duties
- Patricia (Trish) Bayne,
Director, Policy & Government Relations |
No public offices held
- Francois Laflamme,
Director, Government Relations & Innovation |
Public offices held
- Lydia Lanman,
Senior Manager, Policy & Government Relations |
No public offices held
- Kinsley Wilson,
Manager, Policy & Government Relations |
No public offices held
